NKGen Biotech, Inc. entered into a Third Omnibus Amendment to its Secured Convertible Loan Agreement with AlpineBrook Capital GP I Limited, which includes an additional $2,420,000 loan providing net proceeds of $2,200,000. The amendment increases the total consideration shares to 12,953,947 and includes a new promissory note and warrant, both with a conversion or exercise price of $0.08 per share.
